Bedell Cristin advises management on sale of Theramex by CVC to Carlyle and PAI Partners
12 September 2022
Bedell Cristin has advised the management team of Theramex, the global speciality pharmaceuticals company focused on women's health, on Jersey law elements of its sale by CVC Capital Partners VI to global investment firms Carlyle and PAI Partners.
The sale of Theramex will enable the business to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate further international expansion.
Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018 and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health.
Bedell Cristin's team, acting alongside Taylor Wessing, was led by Partner Guy Westmacott, with assistance from fellow Partner Alasdair Hunter and Associate James Peart.